At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 230 target
Drug / intervention
Arlocabtagene Autoleucelbiological
Likely dose
Not stated in record
Key inclusion· 6
- ✓Documented diagnosis of multiple myeloma per IMWG criteria
- ✓At least 4 classes of MM treatment including IMiD, PI, anti-CD38 mAb, anti-BCMA therapy
- ✓At least 3 prior lines of therapy
- ✓Documented disease progression during or after last anti-myeloma regimen per IMWG 2016 criteria
Key exclusion· 4
- ✕Active or history of CNS involvement with MM
- ✕Active systemic fungal, bacterial, viral, or other infection despite appropriate treatment at leukapheresis
- ✕Severe infection, severe sepsis, or bacteremia within 28 days prior to leukapheresis
- ✕Prior GPRC5D-directed therapy without required washout
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company·interventional·Posted Mar 7, 2024·Updated May 28, 2026
In Brief
A Phase 2 clinical trial evaluating Arlocabtagene Autoleucel for Multiple Myeloma. Currently recruiting, targeting 230 participants across 52 sites in 4 countries.
Signals
Enrolling ahead of pace
Detailed Summary
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesAustralia, Canada, Japan, United States
Collaborators--
Timeline
Phase 2Recruiting
202420252026202720282029203020312032
First PostedMar 2024
Enrollment StartMar 2024
TodayJul 2026
Primary CompletionJun 2027
Study CompletionJun 2032
First PostedMar 7, 2024
Enrollment StartMar 21, 2024
Primary CompletionJun 30, 2027
Study CompletionJun 30, 2032
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 2.3 years agoPrimary completion in 12 months
Interventions
Arlocabtagene Autoleucelbiological
Specified dose on specified days